Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | ALPL | P05186 | 1/20 | 0.63 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | GRK2 | P25098 | 1/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2847578 | 0.81 | KDM4E (1.00) | KDM4ECYP1A2ALDH1A1MEN1KMT2A | |
| SCHEMBL8726601 | 0.81 | ALPL (0.71) | KDM4ECYP1A2ALDH1A1MEN1KMT2A | |
| SCHEMBL8808 | 0.78 | ALPL (0.67) | KDM4ECYP1A2ALDH1A1MEN1KMT2A | |
| SCHEMBL21359662 | 0.78 | ALPL (0.67) | KDM4ECYP1A2ALDH1A1MEN1KMT2A | |
| SCHEMBL7819474 | 0.78 | ALPL (1.00) | KDM4ECYP1A2ALDH1A1MEN1KMT2A | |
| SCHEMBL8731546 | 0.78 | KDM4E (0.92) | KDM4ECYP1A2ALDH1A1MEN1KMT2A | |
| SCHEMBL5792174 | 0.78 | ALPL (0.67) | KDM4ECYP1A2ALDH1A1MEN1KMT2A | |
| SCHEMBL8729070 | 0.78 | ALPL (0.67) | KDM4ECYP1A2ALDH1A1MEN1KMT2A | |
| SCHEMBL8726592 | 0.77 | ALPL (0.61) | KDM4ECYP1A2ALDH1A1MEN1KMT2A | |
| SCHEMBL5787498 | 0.77 | ALDH1A1 (0.65) | KDM4ECYP1A2ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1195429-B1 | Automatic dishwashing process and automatic dishwashing compositions having improved anti-corrosion characteristics | HENKEL KGAA (DE) | 2006-06-07 | — | — | EP | claimed |
| US-4276297-A | ANTIULCER AGENTS | PFIZER INC. (US) | 1981-06-30 | — | — | US | claimed |
| US-8277782-B2 | Antiinflammatory agent, metalloproteinase inhibitor, anti-oxidant and modifier of cell redox status, vitamins, inhibitor of activation of nuclear factor kappa beta | THE PROCTER & GAMBLE COMPANY (US) | 2012-10-02 | — | — | US | disclosed |
| EP-1294367-B1 | ORAL COMPOSITIONS COMPRISING HOST-RESPONSE MODULATING AGENT | PROCTER & GAMBLE (US) | 2008-07-16 | — | — | EP | disclosed |
| US-20060193790-A1 | Promoting whole body health | THE PROCTER & GAMBLE COMPANY | 2006-08-31 | — | — | US | disclosed |
| US-20050042283-A1 | Histamine and CCK2/gastrin receptor blockade in the treatment of acid-peptic disease and cancer | UNIVERSITY OF MASSACHUSETTS (US) | 2005-02-24 | — | — | US | disclosed |
| WO-2005007107-A2 | HISTAMINE AND CCK2/GASTRIN RECEPTOR BLOCKADE IN THE TREATMENT OF ACID-PEPTIC DISEASE AND CANCER | UNIVERSITY OF MASSACHUSETTS (US) | 2005-01-27 | — | — | WO | disclosed |
| EP-1294367-A2 | ORAL COMPOSITIONS COMPRISING HOST-RESPONSE MODULATING AGENT | The Procter & Gamble Company (US) | 2003-03-26 | — | — | EP | disclosed |
| WO-2002002096-A2 | ORAL COMPOSITIONS COMPRISING HOST-RESPONSE MODULATING AGENT | THE PROCTER & GAMBLE COMPANY (US) | 2002-01-10 | — | — | WO | disclosed |
| US-5750545-A | EXHIBIT EOSINOPHIL-INHIBITORY ACTION AND LYMPHOCYTE ACTIVATION-INHIBITORY ACTION; USEFUL FOR TREATMENT OF IMMUNE-RELATED DISEASES | THE GREEN CROSS CORPORATION (JP) | 1998-05-12 | — | — | US | disclosed |
| EP-0710654-A1 | TRIAZOLE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | THE GREEN CROSS CORPORATION (JP) | 1996-05-08 | — | — | EP | disclosed |
| US-5364616-A | Use of H-2 antagonists for treatment of gingivitis | THE PROCTER & GAMBLE COMPANY (US) | 1994-11-15 | — | — | US | disclosed |
| US-5294433-A | Dentistry | THE PROCTER & GAMBLE COMPANY (US) | 1994-03-15 | — | — | US | disclosed |
| WO-1993020815-A1 | USE OF H-2 ANTAGONISTS FOR TREATMENT OF GINGIVITIS | THE PROCTER & GAMBLE COMPANY (US) | 1993-10-28 | — | — | WO | disclosed |
| US-4497814-A | 2-(Pyridinyl)-1,2,4-triazolo[1,5-a]pyrimidines and derivatives useful in increasing cardiac contractility | SCHERING CORPORATION (US) | 1985-02-05 | — | — | US | disclosed |
| US-4276297-A | ANTIULCER AGENTS | PFIZER INC. (US) | 1981-06-30 | — | — | US | disclosed |
| US-4276297-A | ANTIULCER AGENTS | PFIZER INC. (US) | 1981-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060193790-A1 | Promoting whole body health | IFNG, TNF, TLR6 | KDM4E 4204/4885CYP1A2 2115/4885ALDH1A1 4304/4885 |
| US-20050042283-A1 | Histamine and CCK2/gastrin receptor blockade in the treatment of acid-peptic disease and cancer | HRH2, CCKBR, GRPR | KDM4E 4168/4885CYP1A2 718/4885ALDH1A1 2969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.